ANGIORESIST PoC is based on the innovative idea of fighting cancer’s therapeutic resistance from a coordinated dual perspective: development of a new biomarker that is able to select which patients will benefit from new inhibitors in therapeutic resistance to current antiangiogenic drugs. We have identified a new predictive companion biomarker that can discriminate metastatic Renal Cell Carcinoma patients that are resistant or responsive to antiangiogenic therapies. Furthermore, this biomarker can be used to select resistant patients that could be treated with an innovative anti-cancer therapeutic target that we have recently discovered. By computational and chemical screening, we have identified hit compounds that will be developed as an effective therapy. Therefore, we now have a predictive companion biomarker that can predict response to antiangiogenics and select the subpopulation of patients to be treated with our novel targeted therapy.
